Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphosarcoma

ablative allogeneic hematopoietic cell transplantation

Wen-Kai Weng

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma

National Institutes of Health (NIH)

Stanford University

Symptoms and General Pathology

Syndrome

Leukemia

Leukemia, Myeloid

Preleukemia

Myelodysplastic Syndromes

Hematologic Neoplasms

Acute Disease

Myeloproliferative Disorders

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Disease Attributes

Chronic Disease

Chronic Graft Versus Host Disease

Acute Graft Versus Host Disease

Chronic Myeloproliferative Disorders

Antineoplastic Agents

All Drugs and Chemicals

Antirheumatic Agents

Etoposide

Cyclophosphamide

Etoposide phosphate

Busulfan

The initial dose utilized will be 1x107 expanded cells/kg. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD.

Robert S Negrin

The purpose of this study is to determine the tolerability and efficacy in treating patients aged 51-60 with acute leukemia and in treating myelodysplastic syndromes (MDS) or myeloproliferative disorders (MPD).

To learn whether a new preparative regimen to prepare patients for bone marrow transplantation is useful in patients above 50 years of age and whether it is useful in patients with myelodysplastic syndromes.

Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies

Allogeneic Sibling and Unrelated Donor Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Busulfan, Etoposide and Cyclophosphamide

Professor of Lymphatic Research and Medicine

Laura Johnston

To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.

Stem Cell Transplantation from Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY). To administer high dose radio-chemotherapy followed by stem cell transplantation from a matched unrelated donor or a partially matched related donor.

Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors

Stem Cell Transplantation From Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY)

Robert Lowsky

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

Allo BMT in Advanced Leukemia or High Grade Lymphoma

Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma	NCT00186394	Lymphoma, Non-H... Blood and Marro... Lymphomas: Non-...	ablative alloge...	18 Years - 61 Years	Stanford University
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies	NCT00186342	Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia	ablative alloge...	51 Years - 60 Years	Stanford University
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors	NCT00186225	Blood Cancer Blood and Marro...	ablative alloge...	4 Weeks - 50 Years	Stanford University
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies	NCT00186342	Acute Disease Myelodysplastic... Leukemia, Myelo... Myeloproliferat... Blood and Marro... Myelodysplastic... Leukemia	ablative alloge...	51 Years - 60 Years	Stanford University
Allo BMT in Advanced Leukemia or High Grade Lymphoma	NCT00186290	Lymphoma, Non-H... Leukemia Blood and Marro... Lymphomas: Non-...	ablative alloge...	- 50 Years	Stanford University
Allo BMT in Advanced Leukemia or High Grade Lymphoma	NCT00186290	Lymphoma, Non-H... Leukemia Blood and Marro... Lymphomas: Non-...	ablative alloge...	- 50 Years	Stanford University

Spots Global Cancer Trial Database for ablative allogeneic hematopoietic cell transplantation